| Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled … H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of clinical oncology 36 (7), 633, 2018 | 1226 | 2018 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 927 | 2018 |
| Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin … KL Chan, K Teo, JG Dumesnil, A Ni, J Tam Circulation 121 (2), 306-314, 2010 | 899 | 2010 |
| Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin … KL Chan, K Teo, JG Dumesnil, A Ni, J Tam Circulation 121 (2), 306-314, 2010 | 899 | 2010 |
| Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer KC Arbour, L Mezquita, N Long, H Rizvi, E Auclin, A Ni, G Martínez-Bernal, ... Journal of Clinical Oncology 36 (28), 2872-2878, 2018 | 867 | 2018 |
| Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer JC Osorio, A Ni, JE Chaft, R Pollina, MK Kasler, D Stephens, C Rodriguez, ... Annals of Oncology 28 (3), 583-589, 2017 | 610 | 2017 |
| Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532, 2018 | 480 | 2018 |
| Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis EE Gardner, BH Lok, VE Schneeberger, P Desmeules, LA Miles, ... Cancer cell 31 (2), 286-299, 2017 | 409 | 2017 |
| Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer KC Arbour, E Jordan, HR Kim, J Dienstag, HA Yu, F Sanchez-Vega, P Lito, ... Clinical cancer research 24 (2), 334-340, 2018 | 396 | 2018 |
| Germline variants in targeted tumor sequencing using matched normal DNA KA Schrader, DT Cheng, V Joseph, M Prasad, M Walsh, A Zehir, A Ni, ... JAMA oncology 2 (1), 104-111, 2016 | 322 | 2016 |
| Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC FC Santini, H Rizvi, AJ Plodkowski, A Ni, ME Lacouture, ... Cancer immunology research 6 (9), 1093-1099, 2018 | 288 | 2018 |
| PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers JK Sabari, GC Leonardi, CA Shu, R Umeton, J Montecalvo, A Ni, R Chen, ... Annals of Oncology 29 (10), 2085-2091, 2018 | 261 | 2018 |
| Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance HA Yu, K Suzawa, E Jordan, A Zehir, A Ni, R Kim, MG Kris, MD Hellmann, ... Clinical Cancer Research 24 (13), 3108-3118, 2018 | 223 | 2018 |
| Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers LA Dunn, EJ Sherman, SS Baxi, V Tchekmedyian, RK Grewal, SM Larson, ... The Journal of Clinical Endocrinology & Metabolism 104 (5), 1417-1428, 2019 | 196 | 2019 |
| Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast … PG Cordeiro, P Ghione, A Ni, Q Hu, N Ganesan, N Galasso, A Dogan, ... Journal of Plastic, Reconstructive & Aesthetic Surgery 73 (5), 841-846, 2020 | 166 | 2020 |
| Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers A Drilon, JJ Lin, T Filleron, A Ni, J Milia, I Bergagnini, V Hatzoglou, ... Journal of Thoracic Oncology 13 (10), 1595-1601, 2018 | 163 | 2018 |
| 18F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma K Ito, R Teng, H Schöder, JL Humm, A Ni, L Michaud, R Nakajima, ... Journal of Nuclear Medicine 60 (3), 335-341, 2019 | 137 | 2019 |
| Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying, JD Soumerai, ... Blood cancer journal 10 (7), 74, 2020 | 126 | 2020 |
| Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders AM Huber, I Gaboury, DA Cabral, B Lang, A Ni, D Stephure, S Taback, ... Arthritis care & research 62 (4), 516-526, 2010 | 125 | 2010 |
| Immunophenotype and response to immunotherapy of RET-rearranged lung cancers M Offin, R Guo, SL Wu, J Sabari, JD Land, A Ni, J Montecalvo, ... JCO precision oncology 3, 2019 | 122 | 2019 |
